Combination therapies and drug delivery platforms in combating pancreatic cancer

Research output: Contribution to journalReview article

Abstract

Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related death in the United States, is highly aggressive and resistant to both chemo- and radiotherapy. It remains one of the most difficult-to-treat cancers, not only due to its unique pathobiological features such as stroma-rich desmoplastic tumors surrounded by hypovascular and hypoperfused vessels limiting the transport of therapeutic agents, but also due to problematic early detection, which renders most treatment options largely ineffective, resulting in extensive metastasis. To elevate therapeutic effectiveness of treatments and overt their toxicity, significant enthusiasm was generated to exploit new strategies for combating PDAC. Combination therapy targeting different barriers to mitigate delivery issues and reduce tumor recurrence and metastasis has demonstrated optimal outcomes in patients' survival and quality of life, providing possible approaches to overcome therapeutic challenges. This paper aims to provide an overview of currently explored multimodal therapies using either conventional therapy or nanomedicines along with rationale, up-to-date progress, as well as the key challenges that must be overcome. Understanding the future directions of the field may assist in the successful development of novel treatment strategies for enhancing therapeutic efficacy in PDAC.

Original languageEnglish (US)
Pages (from-to)682-694
Number of pages13
JournalJournal of Pharmacology and Experimental Therapeutics
Volume370
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

Combination Drug Therapy
Pancreatic Neoplasms
Adenocarcinoma
Therapeutics
Neoplasms
Nanomedicine
Neoplasm Metastasis
Radiotherapy
Quality of Life
Recurrence
Drug Therapy
Survival

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Combination therapies and drug delivery platforms in combating pancreatic cancer. / Lei, Fan; Xi, Xinyuan; Batra, Surinder K.; Bronich, Tatiana K.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 370, No. 3, 01.01.2019, p. 682-694.

Research output: Contribution to journalReview article

@article{dd841a22beff402586a0a0ef59a98ce5,
title = "Combination therapies and drug delivery platforms in combating pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related death in the United States, is highly aggressive and resistant to both chemo- and radiotherapy. It remains one of the most difficult-to-treat cancers, not only due to its unique pathobiological features such as stroma-rich desmoplastic tumors surrounded by hypovascular and hypoperfused vessels limiting the transport of therapeutic agents, but also due to problematic early detection, which renders most treatment options largely ineffective, resulting in extensive metastasis. To elevate therapeutic effectiveness of treatments and overt their toxicity, significant enthusiasm was generated to exploit new strategies for combating PDAC. Combination therapy targeting different barriers to mitigate delivery issues and reduce tumor recurrence and metastasis has demonstrated optimal outcomes in patients' survival and quality of life, providing possible approaches to overcome therapeutic challenges. This paper aims to provide an overview of currently explored multimodal therapies using either conventional therapy or nanomedicines along with rationale, up-to-date progress, as well as the key challenges that must be overcome. Understanding the future directions of the field may assist in the successful development of novel treatment strategies for enhancing therapeutic efficacy in PDAC.",
author = "Fan Lei and Xinyuan Xi and Batra, {Surinder K.} and Bronich, {Tatiana K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1124/jpet.118.255786",
language = "English (US)",
volume = "370",
pages = "682--694",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Combination therapies and drug delivery platforms in combating pancreatic cancer

AU - Lei, Fan

AU - Xi, Xinyuan

AU - Batra, Surinder K.

AU - Bronich, Tatiana K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related death in the United States, is highly aggressive and resistant to both chemo- and radiotherapy. It remains one of the most difficult-to-treat cancers, not only due to its unique pathobiological features such as stroma-rich desmoplastic tumors surrounded by hypovascular and hypoperfused vessels limiting the transport of therapeutic agents, but also due to problematic early detection, which renders most treatment options largely ineffective, resulting in extensive metastasis. To elevate therapeutic effectiveness of treatments and overt their toxicity, significant enthusiasm was generated to exploit new strategies for combating PDAC. Combination therapy targeting different barriers to mitigate delivery issues and reduce tumor recurrence and metastasis has demonstrated optimal outcomes in patients' survival and quality of life, providing possible approaches to overcome therapeutic challenges. This paper aims to provide an overview of currently explored multimodal therapies using either conventional therapy or nanomedicines along with rationale, up-to-date progress, as well as the key challenges that must be overcome. Understanding the future directions of the field may assist in the successful development of novel treatment strategies for enhancing therapeutic efficacy in PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related death in the United States, is highly aggressive and resistant to both chemo- and radiotherapy. It remains one of the most difficult-to-treat cancers, not only due to its unique pathobiological features such as stroma-rich desmoplastic tumors surrounded by hypovascular and hypoperfused vessels limiting the transport of therapeutic agents, but also due to problematic early detection, which renders most treatment options largely ineffective, resulting in extensive metastasis. To elevate therapeutic effectiveness of treatments and overt their toxicity, significant enthusiasm was generated to exploit new strategies for combating PDAC. Combination therapy targeting different barriers to mitigate delivery issues and reduce tumor recurrence and metastasis has demonstrated optimal outcomes in patients' survival and quality of life, providing possible approaches to overcome therapeutic challenges. This paper aims to provide an overview of currently explored multimodal therapies using either conventional therapy or nanomedicines along with rationale, up-to-date progress, as well as the key challenges that must be overcome. Understanding the future directions of the field may assist in the successful development of novel treatment strategies for enhancing therapeutic efficacy in PDAC.

UR - http://www.scopus.com/inward/record.url?scp=85071715620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071715620&partnerID=8YFLogxK

U2 - 10.1124/jpet.118.255786

DO - 10.1124/jpet.118.255786

M3 - Review article

C2 - 30796131

AN - SCOPUS:85071715620

VL - 370

SP - 682

EP - 694

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -